The suitability of [177Lu]Lu-PSMA-617 for the treatment of prostate cancer patients was demonstrated in numerous clinical trials, leading to its FDA approval, its marketing authorization in Great Britain, and the soon-expected approval by the EMA for use in Europe. Here, FOLH1 is linked to prostate carcinoma.